<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725179</url>
  </required_header>
  <id_info>
    <org_study_id>APAP &amp; NAC</org_study_id>
    <nct_id>NCT00725179</nct_id>
  </id_info>
  <brief_title>Treatment of Acetaminophen Toxicity With N-acetylcysteine</brief_title>
  <official_title>Treatment of Acetaminophen Toxicity With Intravenous vs Oral N-acetylcysteine: A Retrospective Review</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akron Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akron Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective chart review of patients who received N-acetylcysteine for APAP toxicity to
      assess length of oral vs IV treatment and overall healthcare costs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of oral vs IV NAC treatment in hours</measure>
    <time_frame>From admission to discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall healthcare costs associated with IV vs Oral NAC treatment</measure>
    <time_frame>From admission to discharge</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Acetaminophen Toxicity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients receiving oral NAC treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients receiving IV NAC treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric and adolescent patients with acetaminophen toxicity
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to CHMCA between June 1, 2004 to May 31, 2008 with a qualifying ICD-9
             diagnosis code for the following APAP overdose situations; poisoning, accidental,
             suicide attempt, therapeutic use, assault, and undetermined (965.4, E850.4, E950.0,
             E935.4, E962.0, E980.0)

          -  Serum APAP concentrations â‰¥ 150 g/mL at 4 hours or a serum concentration above the
             possible hepatotoxic line on the Rumack-Matthew's nomogram if obtained &gt; 4 hours post
             ingestion

          -  Between the ages of 0-21 years

        Exclusion Criteria:

          -  Serum APAP concentrations are not actually documented

          -  Patient did not receive oral or IV NAC treatment

          -  Patient has a preexisting liver disease such as cirrhosis or hepatitis C

          -  Patient &gt; 21 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha Blackford, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHMCA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Medical Center of Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008 Jul 17;359(3):285-92. doi: 10.1056/NEJMct0708278. Review.</citation>
    <PMID>18635433</PMID>
  </reference>
  <reference>
    <citation>Culley CM, Krenzelok EP. A clinical and pharmacoeconomic justification for intravenous acetylcysteine: a US perspective. Toxicol Rev. 2005;24(2):131-43. Review.</citation>
    <PMID>16180933</PMID>
  </reference>
  <reference>
    <citation>Kanter MZ. Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning. Am J Health Syst Pharm. 2006 Oct 1;63(19):1821-7. Review.</citation>
    <PMID>16990628</PMID>
  </reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <last_update_submitted>September 8, 2011</last_update_submitted>
  <last_update_submitted_qc>September 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Akron Children's Hospital</investigator_affiliation>
    <investigator_full_name>Martha Blackford</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <keyword>acetaminophen toxicity</keyword>
  <keyword>n-acetylcysteine</keyword>
  <keyword>liver toxicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

